LungLife AI, INC Result of AGM
06 June 2024 - 2:16AM
RNS Regulatory News
RNS Number : 2975R
LungLife AI, INC
05 June 2024
LungLife AI, Inc.
("LungLife" or the
"Company")
Result of
Annual General
Meeting
LungLife AI (AIM: LLAI), a developer of clinical
diagnostic solutions for lung cancer, announces that at its Annual General
Meeting, held at earlier today, all 10 resolutions put
to members were passed on a poll.
Full details of the voting will be available
shortly on the Company website here:
https://lunglifeai.com/investors/financial-information-documents-presentations/
For further
information please contact:
|
LungLife AI,
Inc.
|
www.lunglifeai.com
|
|
Paul Pagano, CEO
|
Via Walbrook PR
|
|
David Anderson, CFO
|
|
|
|
|
|
Investec Bank plc (Nominated Adviser &
Broker)
|
Tel: +44 (0)20 7597
5970
|
|
Virginia Bull / Cameron MacRitchie / Lydia
Zychowska
|
|
|
|
|
|
Goodbody
(Joint Broker)
|
Tel: +44 (0) 20 3841
6202
|
|
Tom Nicholson / Cameron Duncan
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: +44 (0)20 7933
8780 or LungLifeAI@walbrookpr.com
|
|
Alice Woodings / Phillip
Marriage
|
Mob: 07407
804 654 / 07867 984 082
|
About LungLife
LungLife AI is a developer of
clinical diagnostic solutions designed to make a significant impact
in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the
Company's LungLB® test is designed to deliver additional
information to clinicians who are evaluating indeterminate lung
nodules. For more information visit
www.lunglifeai.com
Our Purpose is to be a driving force in the
early detection to lung cancer. Our Vision is to invert the
20:80 ratio such that in years to come at least 80% of lung cancer
is detected early.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGEAKKSEFLLEFA
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Dec 2023 to Dec 2024
